Mizuho Securities Downgrades Quest Diagnostics (DGX) to Neutral
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Mizuho Securities downgraded Quest Diagnostics (NYSE: DGX) from Buy to Neutral with a price target of $86.00 (from $84.00) on valuation after solid run.
Analyst Ann Hynes commented, "We are downgrading DGX from Buy to Neutral. Since we upgraded the stock on March 1, 2016, DGX (+26%) has outperformed the S&P 500 Healthcare (+10%) and S&P 500 (+13%). The reason for the downgrade is simple: valuation. Our new price target of $86 is based on 17.0x our 2017E adjusted EPS which is the “high” trading average for the clinical laboratory group over the past ten-years. We cannot justify a higher multiple that would be required to maintain a Buy rating. We remain positive on the operational outlook and management team of DGX."
Shares of Quest Diagnostics closed at $83.54 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BMO Capital Raises Price Target on ManpowerGroup (MAN) Following 3Q Surprise
- Wedbush Raises Price Target on Citizens Financial Group (CFG) Following 3Q EPS Beat
- Oppenheimer Raises Price Target on Microsoft (MSFT) to $65 Following 1Q Beat
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change, Downgrades
Related EntitiesStandard & Poor's
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!